News from durect corporation

Jun 26, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Secures $20 Million Debt Financing

DURECT Corporation (Nasdaq: DRRX) today announced that it had entered into a Loan and Security Agreement (the "Loan Agreement") with Oxford Finance...

Jun 09, 2014, 08:00 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT to Present at The Wall Street Analyst Forum Institutional Investor Conference

DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, will be presenting at The 25th Annual Wall Street...

May 16, 2014, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the International Anesthesia Research Society (IARS) Annual Meeting

 DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for...

May 07, 2014, 08:30 ET

DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting

 DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and CEO of DURECT Corporation, will be an industry speaker at...

May 01, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces First Quarter 2014 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2014.  Total revenues were $6.3 million and net...

Apr 23, 2014, 17:40 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Invites You to Join its First Quarter 2014 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) first quarter 2014 financial results press release, you are invited to listen to the...

Apr 01, 2014, 16:15 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentations at the 39th Annual American Society of Regional Anesthetic and Pain Medicine Meeting

 DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR™ (SABER®-Bupivacaine), an investigational drug for...

Feb 27, 2014, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces Fourth Quarter 2013 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2013. Total revenues were $4.3 million...

Feb 18, 2014, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Invites You to Join its Fourth Quarter 2013 Earnings Conference Call and Upcoming Investor Conference

 In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2014 financial results press release, you are invited to listen to the...

Feb 12, 2014, 16:43 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Receives Complete Response Letter from FDA for POSIDUR™ (SABER®-Bupivacaine)

DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for...

Nov 13, 2013, 16:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces Closing of Public Offering of Common Stock

DURECT Corporation (Nasdaq: DRRX) today announced the closing of an underwritten public offering of 7,142,858 shares of its common stock, offered...

Nov 08, 2013, 08:30 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces Pricing of Public Offering of Common Stock

DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 7,142,858 shares of its common stock, offered...

Nov 07, 2013, 16:01 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces Proposed Public Offering of Common Stock

DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten...

Nov 04, 2013, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the third quarter of 2013. Total revenues were $3.0 million for the three...

Oct 28, 2013, 16:15 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call

In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2013 financial results press release, you are invited to listen to the...

Oct 22, 2013, 08:10 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

Pfizer Proceeding with REMOXY® Development

 DURECT Corporation (Nasdaq: DRRX) announced today that Pfizer Inc. (NYSE: PFE) has stated that, having achieved technical milestones related...

Sep 27, 2013, 08:00 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces Changes to its Board of Directors

DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26, 2013. ...

Sep 03, 2013, 16:38 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT to Participate in Upcoming Healthcare Conferences

 DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences....

Aug 05, 2013, 16:05 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2013. Total revenues were $3.9 million for the three...

Aug 01, 2013, 08:00 ET
DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic
                                                                                                                                                                                                                        debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)

DURECT Announces Selection with Orient PHARMA of Lead Formulation for ORADUR®-Methylphenidate

DURECT Corporation (Nasdaq: DRRX) today announced that it and its collaborator Orient PHARMA Co., Ltd., a diversified multinational...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer